Department of Cardiothoracic Surgery, Heart Center and Center of Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Cardiovasc Ther. 2011 Feb;29(1):2-16. doi: 10.1111/j.1755-5922.2010.00191.x. Epub 2010 Oct 14.
Although significant advances have been made in terms of pharmacological, catheter-based, and surgical palliation, heart failure remains a fatal disease. As a curative concept, regenerative medicine aims at the restoration of the physiologic cellular composition of diseased organs. So far, clinical cardiac regeneration attempts have only been moderately successful, but a better understanding of myocardial cell homeostasis and somatic as well as embryonic stem cell biology has opened the door for the development of more potent therapeutic cardiac regeneration strategies. Accumulating evidence indicates that the postnatal mammalian heart retains a pool of tissue-specific progenitor cells and is also repopulated by cells from extracardiac sources. However, this intrinsic myocardial regeneration potential clearly needs to be augmented by either manipulation of the cell cycle of differentiated cells, activation of resident cardiac progenitor cells, and/or the transplantation of exogenous cells. This review summarizes the recent developments in cardiac regenerative medicine, many of which may find their way into the clinical setting in the foreseeable future.
尽管在药理学、基于导管的和手术姑息治疗方面取得了重大进展,但心力衰竭仍然是一种致命的疾病。作为一种治疗概念,再生医学旨在恢复患病器官的生理细胞组成。到目前为止,临床心脏再生尝试仅取得了适度的成功,但对心肌细胞动态平衡以及体细胞核和胚胎干细胞生物学的更好理解为开发更有效的心脏再生治疗策略打开了大门。越来越多的证据表明,出生后哺乳动物的心脏保留了一组组织特异性祖细胞,并且也被来自心脏外来源的细胞重新填充。然而,这种内在的心肌再生潜力显然需要通过操纵分化细胞的细胞周期、激活驻留的心肌祖细胞和/或移植外源性细胞来增强。这篇综述总结了心脏再生医学的最新进展,其中许多进展可能在可预见的未来在临床环境中找到应用。